Cellular Origins and CGT Catapult partner to automate manufacturing
Cellular Origins and the Cell and Gene Therapy Catapult (CGT Catapult) have announced a new collaboration to demonstrate universal automation of CGT manufacturing.
Stay updated with breaking news from Cellular Origin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cellular Origins and the Cell and Gene Therapy Catapult (CGT Catapult) have announced a new collaboration to demonstrate universal automation of CGT manufacturing.
Partnership to develop and implement Cellular Origins' robotic platform Constellation for universal automation of CGT manufacturing at CGT Catapult's Stevenage Manufacturing Innovation Centre Cellular
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specializing in the advancement of the cell and gene therapy industry, today announced a collaboration to demonstrate universal automation of CGT manufacturing.
TTP Company Cellular Origins has appointed Peter Crossley as Chief Operating Officer (COO), to bolster Cellular Origins’ mission to develop scalable automation solutions for cell therapy manufacture. Click to read more...
Renowned experts from across the CGT and robotics industries, Professor John Campbell, Dr Matthew Li, Dr Paul Roberts, and Geoffrey Hodge appointed to provide strategic and technical perspectives.